Clinical Trials Browser

Unknown × Triple Negative Breast Neoplasms × Capecitabine × Clear all

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04395989 2023-12-22

FUTURE-SUPER

Phase 2 Unknown

139 enrolled

Breast

Triple Negative Breast Neoplasms

NCT05390476 2022-11-04

Tucidinostat and Metronomic Capecitabine for Metastatic Triple-negative Breast Cancer:a Multicenter,Open-label, Randomized Controlled, Phase II Clinical Trial

Phase 2 Unknown

126 enrolled

Breast

Triple Negative Breast Neoplasms

NCT03805399 2022-08-10

FUTURE

Phase 1/2 Unknown

140 enrolled

Breast

Triple Negative Breast Neoplasms

NCT05438706 2022-06-30

A Clinical Study of the Efficacy and Safety of Chidamide in Combination With Camrelizumab and Carboplatin or Capecitabine in the Second and Third Line Treatment of Relapsed/Metastatic Triple-negative Breast Cancer

Phase 2 Unknown

70 enrolled

Breast

Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT04745975 2022-04-20

Guided Treatment Based on Mini-PDX in Metastatic Triple Negative Breast Cancer

Phase 2 Unknown

100 enrolled

Breast

Triple Negative Breast Neoplasms

NCT05089643 2022-01-10

Anrotinib in Combination With Capecitabine in Advanced Triple Negative Breast Cancer

Phase 2 Unknown

35 enrolled

Breast

Triple Negative Breast Neoplasms

NCT03044730 2020-07-13

Pembrolizumab and Capecitabine in Treating Patients With Locally Advanced or Metastatic Triple Negative or Hormone-Refractory Breast Cancer That Cannot Be Removed by Surgery

Phase 2 Unknown

30 enrolled 11 charts

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03775928 2018-12-14

Compare Apatinib Plus Capecitabine Versus Capecitabine in Maintenance Therapy for Patients With Advanced Triple-negative Breast Cancer

Phase 2 Unknown

80 enrolled

Breast

Triple Negative Breast Neoplasms

NCT01642771 2017-04-19

Comparative Study on Two Post-operative Adjuvant Chemotherapy Regimens for Treating Triple-negative Breast Cancer

Phase 3 Unknown

636 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01928680 2015-02-23

Phase II Study of Capecitabine and Cisplatin to Treat Metastatic Triple Negative Breast Cancer

Phase 2 Unknown

33 enrolled 5 charts

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

Clinical Trials

BreastImmune03

FUTURE-SUPER

Tucidinostat and Metronomic Capecitabine for Metastatic Triple-negative Breast Cancer:a Multicenter,Open-label, Randomized Controlled, Phase II Clinical Trial

FUTURE

A Clinical Study of the Efficacy and Safety of Chidamide in Combination With Camrelizumab and Carboplatin or Capecitabine in the Second and Third Line Treatment of Relapsed/Metastatic Triple-negative Breast Cancer

Guided Treatment Based on Mini-PDX in Metastatic Triple Negative Breast Cancer

Anrotinib in Combination With Capecitabine in Advanced Triple Negative Breast Cancer

Pembrolizumab and Capecitabine in Treating Patients With Locally Advanced or Metastatic Triple Negative or Hormone-Refractory Breast Cancer That Cannot Be Removed by Surgery

Compare Apatinib Plus Capecitabine Versus Capecitabine in Maintenance Therapy for Patients With Advanced Triple-negative Breast Cancer

Comparative Study on Two Post-operative Adjuvant Chemotherapy Regimens for Treating Triple-negative Breast Cancer

Phase II Study of Capecitabine and Cisplatin to Treat Metastatic Triple Negative Breast Cancer